# Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

> **NCT00531479** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 459 (actual)

## Conditions studied

- Aspergillosis

## Interventions

- **DRUG:** voriconazole
- **DRUG:** anidulafungin
- **DRUG:** voriconazole

## Key facts

- **NCT ID:** NCT00531479
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-04
- **Final completion:** 2011-05
- **Target enrollment:** 459 (ACTUAL)
- **Last updated:** 2012-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531479, "Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00531479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*